GRÙTHAN BIOSCIENCE LLC
making the impossible possible
 |  |  |
|---|---|---|
 |  |  |
OUR STORY
Grùthan = liver (Scottish Gaelic)
A new era in drug discovery
Grùthan Bioscience has a mission to use stem cell based approaches to develop new treatments for rare liver diseases.
​
Inborn errors in metabolism are a group of diseases, which primarily affect the liver. Examples of such disorders include those that affect cholesterol levels, glycogen storage, mitochondrial function, and amino acid metabolism.
Our plan is to develop Grùthan Bioscience as a world leader in generating new, effective medicines for the treatment of liver disease.
OUR FOUNDER
Dr. Stephen Duncan received his D.Phil. from Oxford University in 1992 for working on the mechanisms that controlled transmission of poxviruses. He moved to the Rockefeller University in New York City to study transcriptional regulation of liver development.
In 1997 he joined the Medical College of Wisconsin in Milwaukee. As the Stephen Marcus Professor in Human and Molecular Genetics he established a pioneering stem cell laboratory to study orphan diseases. In 2015 Dr. Duncan relocated to the Medical University of South Carolina in Charleston, where he is currently the Chair of the Department of Regenerative Medicine and Cell Biology.
His research focuses on the use of stem cells to understand liver diseases that primarily affect children. His group has developed technologies to control the differentiation of pluripotent stem cells into hepatocytes. Researchers in his laboratory have exploited this system to model rare diseases of liver metabolism and as a platform for drug discovery. Dr. Duncan established Grùthan Bioscience in 2019 to develop new cures for untreatable diseases of the liver.
OUR TECHNOLOGY
Efficient Innovative Successful
Induced pluripotent stem cells (iPSCs) can be generated from the blood of patients. At Grùthan Bioscience, we have advanced the study of liver disease, by showing that liver cells can be produced from a patient’s iPSCs.
This advance means that we have unlimited access to any patient’s liver cells without the need for invasive procedures. By using iPSC–derived liver cells to model liver disease, we have devised a new platform for drug discovery.
​The platform has been used successfully to identify therapeutics for the potential treatment of excessive cholesterol and mitochondrial diseases.
OUR PHILOSOPHY
Everything is theoretically impossible, until it is done.
Robert A. Heinlein
GET IN TOUCH
Grùthan Bioscience LLC
4843 Marshwood Drive
Hollywood SC 29949
​
​